tyc7111cc太阳成集团

    洞察市场格局
    解锁药品研发情报

    免费客服电话

    18983288589
    医药数据查询

    【ChiCTR2100050197】The effectiveness of MICM to improve medication adherence for dual-diagnosed patients

    基本信息
    登记号

    ChiCTR2100050197

    试验状态

    尚未开始

    药物名称

    /

    药物类型

    /

    规范名称

    /

    首次公示信息日的期

    2021-08-22

    临床申请受理号

    /

    靶点

    /

    适应症

    SUBSTANCE USE DISORDER WITH ANY TYPE OF PSYCHIATRIC DISORDERS

    试验通俗题目

    The effectiveness of MICM to improve medication adherence for dual-diagnosed patients

    试验专业题目

    A pilot randomized controlled trial of integrative Motivational Interviewing and Contingency Management program (MICM) for dual-diagnosed patients to enhance psychiatric medication adherence

    申办单位信息
    申请人联系人
    申请人名称
    联系人邮箱
    联系人邮编

    联系人通讯地址
    临床试验信息
    试验目的

    The proposed project will adopt a single-blinded, multi-centre pilot randomized controlled trial (RCT) design to determine the feasibility and preliminary effectiveness of a multi-model, integrative Motivational Interviewing and Contingency Management program (MICM), in comparison with the usual care (i.e., case management), at immediately after intervention and 3-months post-intervention. The following outcomes will be assessed: 1. medication adherence (primary outcome); and 2. psychiatric symptoms, frequency of substance abuse and psychiatric hospitalizations (secondary outcomes). Moreover, the perceived usefulness and areas of improvement of the MICM program will be evaluated to make necessary improvement in the future clinical application.

    试验分类
    试验类型

    随机抽样

    试验分期

    Ⅰ期

    随机化

    Block randomization with block size of 6-8 will be used to maintain a balanced number of participants in both groups (Efird, 2011). A sequence of group identifiers (I or C) based on computer-generated random codes is prepared in advance and put in serially numbered sealed opaque envelopes by a clerical&

    盲法

    The researcher who is also the intervention deliverer will not know which participant will be assigned to which group before opening of opaque envelope. After allocation has been done, both participants and researcher cannot be blinded.

    试验项目经费来源

    SELF

    试验范围

    /

    目标入组人数

    43

    实际入组人数

    /

    第一例入组时间

    2021-08-23

    试验终止时间

    2022-12-31

    是否属于一致性

    /

    入选标准

    1. Adults, aged 18-64 years Hong Kong residents; 2. Diagnosed with substance-use disorder and comorbid with at least one type of other mental disorder in the Diagnostic and Statistical Manual – fourth version (text revised) (DSM-IV-TR) / fifth version (DSM-5), or International Classification of Diseases – 10th (ICD-10) / 11th version (ICD-11); 3. Able to give written consent as recommended by psychiatrist and read/write Chinese language; 4. Being prescribed at least one type of oral psychiatric medication.;

    排除标准

    1. Having organic psychiatric disorder AND/OR learning disability; 2. Having been prescribed depot-only (injection) medication or no medication; 3. Having visual, language or communication difficulties.;

    研究者信息
    研究负责人姓名
    试验机构

    N/A

    研究负责人电话
    研究负责人邮箱
    研究负责人邮编

    /

    联系人通讯地址

    N/A的其他临床试验

    更多

    最新临床资讯

    tyc7111cc太阳成集团企业版
    50亿+条医药数据随时查
    7天免费试用
    体验产品